Abstract

Background

Polytrauma is a major clinical problem due to its impact on morbidity and mortality, especially among the younger population. Its pathophysiology is not completely elucidated, and the study of the involvement of certain cell populations with therapeutic potential, such as mesenchymal stromal cells (MSCs), is an area of growing interest, as mesenchymal cells have anti-inflammatory, immunoregulatory, and osteogenic potential.

Methods

In the present preliminary work, we have evaluated the characteristics of MSCs in terms of proliferation, immunophenotype, cell cycle, clonogenic capacity, and multilineage differentiation ability in a series of 18 patients with polytrauma and compared them to those from otherwise healthy patients undergoing elective spinal surgery.

Results

MSCs from polytrauma patients displayed higher proliferative potential with significantly higher cumulative population doublings, increased expression of some important cell adhesion molecules (CD105, CD166), and an early pre-osteogenic differentiation ability compared to those of the control group.

Conclusions

MSCs could potentially be of help in the repair process of polytrauma patients contribute to both cell-tissue repair and anti-inflammatory response. This potential should be further explored in larger studies.

Details

Title
MSCs from polytrauma patients: preliminary comparative study with MSCs from elective-surgery patients
Author
López, Raúl; Martí-Chillón, Gerardo J; Blanco, Juan F  VIAFID ORCID Logo  ; da Casa, Carmen; González-Robledo, Javier; Pescador, David; Preciado, Silvia; Muntión, Sandra; Sánchez-Guijo, Fermín
Pages
1-11
Section
Research
Publication year
2021
Publication date
2021
Publisher
BioMed Central
e-ISSN
17576512
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2562556100
Copyright
© 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.